Latest Strategic Growth News

IODM Limited reported a decline in cash reserves to $461,000 for the December quarter, while projecting revenue growth through new university client onboarding in the UK and North America.

Hartshead Resources reports a robust December quarter with strategic progress on UK gas developments, fiscal clarity from government levy changes, and the acquisition of new licenses boosting its resource base.

Firetail Resources reports strong drilling results at its Skyline Copper Project in Newfoundland and gains strategic support through the BHP Xplor 2025 program, positioning the company for accelerated exploration growth.

Credit Clear Limited has reported a robust first half of FY25 with record revenue and a significant rise in profitability, reaffirming its full-year guidance amid strong client acquisition.

Connexion Mobility Limited reported a robust 15% revenue increase and a 43% jump in profit after tax for the half-year ended December 2024, underscoring its growing foothold in automotive SaaS solutions while continuing to invest in future growth.

Elixinol Wellness delivered a standout Q4 FY24 performance with a 71% jump in cash receipts and a 64% rise in revenue, driven by key acquisitions and operational efficiencies. The company edges closer to EBITDA break-even, setting the stage for growth in 2025.

MONEYME reports a 54% surge in loan originations and a $1.4 billion loan book in 2Q25, underpinned by fresh growth capital and a strategic shift to secured lending.

LiveHire’s 2Q25 report reveals a sharp rise in operating cash outflows and a dip in SaaS revenue, offset by strong growth in its North American Direct Sourcing business and a strategic capital raise amid an ongoing takeover.

archTIS Limited reported a 12% increase in annual recurring revenue to $4 million and achieved net positive cash flow from operations, while signing a binding term sheet to acquire Direktiv’s assets, signaling strategic growth in data-centric security.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Stonehorse Energy Limited outperformed production forecasts in Q4 2024 despite a revenue dip caused by weak natural gas prices, while advancing new project negotiations in Canada and the US.

TZ Limited reported a quarterly revenue shortfall in Q2 FY2025 due to delayed US projects but anticipates a strong rebound post-election and strategic growth through acquisition.